SEOUL, South Korea, September 1, 2026 — Lynk Solutec, led by co-CEOs Jungmok Seo and Yeontaek Lee, presented at the “2026 First Technology-Based IR Meetup” held at BigPlace in Gangnam-gu, Seoul. The event was jointly hosted by the Ministry of Trade, Industry and Energy, the Korea Institute for Advancement of Technology (KIAT), and the Korea Institute for Materials, Parts and Equipment Investment Institutions (KITIA). It brought together eight consortia selected from 28 companies in the first phase (business model planning) of the 2026 Scale-up Technology Commercialization Program, along with eight venture capital investment managers, for a total of about 30 participants.

CEO Yeontaek Lee presented on behalf of Lynk Solutec, outlining the company’s progress in developing surface coating solutions for medical devices and its commercialization results to date. Following the presentation, the company held one-on-one investment consultations with eight domestic venture capital firms, including Boditech Ventures and Wonik Investment Partners.

The event concluded with a business model planning roundtable for companies and their affiliated research organizations participating in the Scale-up program. Lynk Solutec, in a consortium with FNP Partners, is carrying out a project titled “Development of Innovative Medical Devices Applying Anti-Biofouling Coating (Lynk Coating),” and discussed collaboration progress and future support needs at the session.

“This was an opportunity to explain our validated coating technology directly to investors, based on results we’ve built in the medical device sector,” said Yeontaek Lee, CEO of Lynk Solutec. “We plan to continue these investment discussions, including our direction toward expanding into industrial coating applications.”

The company plans to continue follow-up discussions with the domestic venture capital firms it met through the investment consultation sessions.

About Lynk Solutec
Lynk Solutec (lynksolutec.com) is a South Korean medical device company specializing in ophthalmic and urological surgical products. The company develops and commercializes the LYNKS product line, including the LYNKS Frontalis Suspension Set — a rare medical device designation product currently advancing through clinical trials toward U.S. market entry. Lynk Solutec holds FDA Class I registration and GMP Certificate of Conformity for its lead product, and is actively expanding its global presence through international trade shows and regulatory milestones.

(END)

Study led by Lynk Solutec researchers, published in a peer-reviewed journal with an impact factor of 8.2

SHIELD-C cap demonstrated optical transmittance above 90% and separately verified suppression of blood and mucus adhesion

Kayoung Son, former Lynk Solutec researcher, listed as first author; co-CEOs Yeontaek Lee and Jungmok Seo among co-authors

SEOUL, South Korea, June 10, 2026 — Lynk Solutec, a South Korean medical device company, announced that a paper on its endoscopic visualization technology was published on June 10, 2026, in ACS Applied Materials & Interfaces, a peer-reviewed journal with an impact factor of 8.2.

The paper, titled “Disposable Endoscope Cap Maintaining Clear Surgical Visualization under Fogging and Fouling,” lists Kayoung Son, a former researcher at Lynk Solutec, as first author, with co-CEOs Yeontaek Lee and Jungmok Seo among the co-authors. Clinical advisors, including Dr. Seung-No Hong of Seoul National University Hospital and Dr. Seung Hoon Lee of Korea University Ansan Hospital, also contributed as co-authors.

The study presents SHIELD-C, a single-use, snap-on endoscope cap developed by Lynk Solutec, built on a bilayer structure combining a covalently bonded PDMS brush base layer with a silicone oil top layer. The cap maintained optical transmittance above 90% across the visible range. Separately, it demonstrated effective suppression of blood and mucus adhesion on its surface. During surgery, its surface function can be restored immediately through simple lubricant replenishment, allowing visualization to be maintained without interrupting the surgical workflow. Durability and optical stability were also validated across a range of conditions, including ex vivo surgical models.

“This publication confirms that the core technology behind our endoscope products has been validated at an international academic level,” said Yeontaek Lee, CEO of Lynk Solutec. “Having confirmed its effectiveness in real surgical settings through collaboration with our clinical advisors, we will apply these findings directly to product advancement and market expansion.”

Lynk Solutec continues to pursue clinical and academic validation both domestically and internationally, centered on its endoscope product line (C.E.V., Clean View), as it advances into global markets.

(END)